Alaska Clinical Research Center, Llc

Anchorage, Alaska 99508

0 studies enrolling now · 22 studies all time

What they study most

Bladder Cancer, Bladder Neoplasm, Carcinoma in Situ, Carcinoma, Transitional Cell, Castration-Resistant Prostate Cancer, Hormone-Refractory Prostate Cancer, Mycobacterium, Neoplasm Recurrence, Local, Peyronie's Disease, Prostate Cancer, Prostate Cancer Metastatic, Prostatic Neoplasms

Studies at this site

• Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma — Completed
• Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611) — Completed
• A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer — Completed
• Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer — Stopped early
• Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer — Completed
• Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease — Completed
• Study of AA4500 in the Treatment of Peyronie's Disease — Completed
• Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer — Stopped early
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer — Completed
• Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• Efficacy Study of ABR-215050 to Treat Prostate Cancer — Completed
• R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence — Status unconfirmed
• The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer — Completed
• YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy — Stopped early
• A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer — Completed
• A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer — Completed
• Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis — Completed
• Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer — Completed
• Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer — Completed
• Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure — Completed
• A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer — Completed